- Home
- PRLD vs IFRX Comparison
PRLD vs IFRX Comparison
Compare PRLD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- IFRX
- Stock Information
- Founded
- PRLD 2016
- IFRX 2007
- Country
- PRLD United States
- IFRX Germany
- Employees
- PRLD N/A
- IFRX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- IFRX Health Care
- Exchange
- PRLD Nasdaq
- IFRX Nasdaq
- Market Cap
- PRLD 48.6M
- IFRX 53.5M
- IPO Year
- PRLD 2020
- IFRX 2017
- Fundamental
- Price
- PRLD $0.78
- IFRX $0.79
- Analyst Decision
- PRLD Strong Buy
- IFRX Strong Buy
- Analyst Count
- PRLD 2
- IFRX 4
- Target Price
- PRLD $4.50
- IFRX $7.75
- AVG Volume (30 Days)
- PRLD 221.0K
- IFRX 282.5K
- Earning Date
- PRLD 08-11-2025
- IFRX 08-07-2025
- Dividend Yield
- PRLD N/A
- IFRX N/A
- EPS Growth
- PRLD N/A
- IFRX N/A
- EPS
- PRLD N/A
- IFRX N/A
- Revenue
- PRLD $7,000,000.00
- IFRX $140,242.00
- Revenue This Year
- PRLD N/A
- IFRX N/A
- Revenue Next Year
- PRLD N/A
- IFRX $6,309.47
- P/E Ratio
- PRLD N/A
- IFRX N/A
- Revenue Growth
- PRLD N/A
- IFRX 30.90
- 52 Week Low
- PRLD $0.61
- IFRX $0.71
- 52 Week High
- PRLD $6.80
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- PRLD 42.16
- IFRX 37.43
- Support Level
- PRLD $0.77
- IFRX $0.78
- Resistance Level
- PRLD $0.84
- IFRX $0.83
- Average True Range (ATR)
- PRLD 0.07
- IFRX 0.04
- MACD
- PRLD -0.02
- IFRX 0.03
- Stochastic Oscillator
- PRLD 16.04
- IFRX 52.00
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.